| Forsyth, Peter |
| Recruiting | 3 | 740 | Europe | R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, Ninlaro, Revlimid, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance, R2: Lenalidomide + ixazomib maintenance | University of Leeds, Cancer Research UK, Takeda, Celgene | Multiple Myeloma | 12/24 | 12/24 | | |
ACCoRd, NCT03562169: The Role of Ixazomib in Autologous Stem Cell Transplant in Relapsed Myeloma - Myeloma XII |
|
|
| Recruiting | 3 | 406 | Europe | Ixazomib, thalidomide, & dexamethasone (ITD) re-induction, Conventional autologous stem cell transplant (ASCT-con), Augmented autologous stem cell transplant (ASCT-aug), ITD consolidation and ixazomib maintenance vs. No further therapy | University of Leeds, Cancer Research UK, Takeda | Multiple Myeloma | 03/26 | 03/27 | | |
| Recruiting | 2/3 | 1030 | Europe, Canada, US, RoW | Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase | Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group | Glioblastoma | 06/26 | 06/28 | | |
|
|
NCI-2020-01520, NCT04348747: Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer |
|
|
| Recruiting | 2 | 23 | US | Anti-HER2/HER3 Dendritic Cell Vaccine, Anti-HER2/3 DC Vaccine, Anti-HER2/3 Dendritic Cell Vaccine, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475 | Roswell Park Cancer Institute, United States Department of Defense | Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8 | 06/25 | 12/26 | | |
NCT02681549: Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 42 | US | Pembrolizumab plus Bevacizumab | Yale University, National Cancer Institute (NCI), Merck Sharp & Dohme LLC | Melanoma, Non-small Cell Lung Cancer, Brain Metastasis | 04/25 | 08/25 | | |
NCT04588545: Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease |
|
|
| Recruiting | 1/2 | 39 | US | Radiation Therapy, Pertuzumab, Trastuzumab | H. Lee Moffitt Cancer Center and Research Institute, Genentech, Inc. | HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease | 07/25 | 07/25 | | |
MCC-20899, NCT04923542: Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases |
|
|
| Recruiting | 1/2 | 31 | US | Stereotactic Radiosurgery (SRS), Abemaciclib, Verzenio, Ramiven, Endocrine therapy, hormone therapy | H. Lee Moffitt Cancer Center and Research Institute, Eli Lilly and Company | Brain Metastases, HR+ Metastatic Breast Cancer | 03/25 | 03/26 | | |
NCT03426891: Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma |
|
|
| Completed | 1 | 21 | US | Pembrolizumab, Keytruda, immunotherapy, Vorinostat, Zolinza™, chemotherapy, histone deacetylase inhibitor, Temozolomide, Temodar, TMZ, Radiotherapy, radiation therapy | H. Lee Moffitt Cancer Center and Research Institute, Merck Sharp & Dohme LLC | Glioblastoma, Brain Tumor, GBM | 10/21 | 06/23 | | |
NCT03719768: Avelumab With Radiotherapy in Patients With Leptomeningeal Disease |
|
|
| Completed | 1 | 16 | US | Avelumab, Bavencio, Whole Brain Radiotherapy, WBRT | H. Lee Moffitt Cancer Center and Research Institute, Pfizer | Leptomeningeal Metastases, Leptomeningeal Disease | 07/22 | 08/24 | | |
NCT03927274: Intratumorally-Administered Topotecan Using Convection-Enhanced Delivery in Patients With Grade III/ IV Glioma |
|
|
| Terminated | 1 | 3 | US | Topotecan | H. Lee Moffitt Cancer Center and Research Institute | Glioma of Brain | 05/23 | 05/23 | | |
NCT06463184: Study to Assess Xevinapant in Preoperative Subjects With Recurrent High-Grade Glioma (rHGG) |
|
|
| Withdrawn | 1 | 12 | NA | Xevinapant, Debio 1143 | H. Lee Moffitt Cancer Center and Research Institute, EMD Serono Research & Development Institute, Inc. | Recurrent High-grade Glioma | 06/27 | 06/27 | | |
| Recruiting | 1 | 18 | US | Dendritic Cell Vaccine | H. Lee Moffitt Cancer Center and Research Institute, United States Department of Defense | Leptomeningeal Disease, Triple Negative Breast Cancer, HER2-positive Breast Cancer | 03/26 | 03/26 | | |
CA209-6D9, NCT05704933: Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases |
|
|
| Active, not recruiting | 1 | 16 | US | Nivolumab, Opdivo, Ipilimumab, Yervoy, Nivolumab + Relatlimab, Opdualag, Standard of Care Craniotomy | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb | Metastatic Melanoma, Metastasis to Brain | 06/24 | 06/25 | | |
NCT04268979: Electronic Social Network Assessment Program (eSNAP) + Caregiver Navigator |
|
|
| Active, not recruiting | N/A | 296 | US | eSNAP, Electronic Social Network Assessment Program, Caregiver Navigator | H. Lee Moffitt Cancer Center and Research Institute | Brain Cancer | 07/24 | 07/25 | | |
NCT03115333: DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma |
|
|
| Recruiting | N/A | 146 | US | Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, DSC-MRI, Dynamic Susceptibility Contrast-Enhanced MRI, DYNAMIC SUSCEPTIBILITY-CONTRAST MRI | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Gliosarcoma, Recurrent Glioblastoma | 05/25 | 05/27 | | |
| Khimani, Farhad |
E-CELERATE, NCT05181540: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation |
|
|
| Terminated | 3 | 130 | US | AB-205, E-CEL cells, Placebo | Angiocrine Bioscience, California Institute for Regenerative Medicine (CIRM) | Hodgkin Lymphoma, Non Hodgkin Lymphoma | 12/23 | 01/25 | | |
NCT04745559: Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy |
|
|
| Recruiting | 2 | 26 | US | Pneumococcal conjugate vaccine (PCV13), Prevnar 13, CD19 targeted CAR T Cell Therapy | H. Lee Moffitt Cancer Center and Research Institute | Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL), High-grade B-cell Lymphoma (HGBCL), Follicular Lymphoma | 04/25 | 12/25 | | |
ACCESS, NCT04904588: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide |
|
|
| Recruiting | 2 | 300 | US | Busulfan, Busulfex®, Fludarabine, Fludara®, Total-body irradiation, TBI, Cyclophosphamide, Cytoxan®, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, Bone Marrow Hematopoietic Stem Cell Transplantation, BM HSCT, BM HCT, Bone Marrow Transplantation, Post-transplant Cyclophosphamide, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient-Reported Outcomes | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma | 07/24 | 07/24 | | |
NCT06553872: Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL |
|
|
| Recruiting | 2 | 60 | US | Pirtobrutinib, Jaypirca, Brexucabtagene Autoleucel, Tecartus | H. Lee Moffitt Cancer Center and Research Institute, Bankhead-Coley Florida Biomedical Research Program, Eli Lilly and Company | Mantle Cell Lymphoma | 08/29 | 08/29 | | |
NCT06660355: Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic Therapy |
|
|
| Recruiting | 2 | 120 | US | Ruxolitinib, Prednisone | H. Lee Moffitt Cancer Center and Research Institute, Incyte Corporation | Chronic Graft-versus-host Disease (cGVHD) | 11/28 | 11/28 | | |
NCT06760156: Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym |
|
|
| Recruiting | 2 | 28 | US | Tafasitamab, Lenalidomide | H. Lee Moffitt Cancer Center and Research Institute, Incyte Corporation | Large B-cell Lymphoma | 01/27 | 01/28 | | |
OPTIMIZE, NCT06001385: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation with Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis |
|
|
| Recruiting | 2 | 190 | US | Busulfan, Busulfex®, Fludarabine, Fludara®, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, PBSCT, Post-Transplant Cyclophosphamide, Cytoxan®, PTCy, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient Reported Outcomes, PRO, Melphalan, Total-body irradiation, TBI, Cyclophosphamide | Center for International Blood and Marrow Transplant Research, National Marrow Donor Program | Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis | 02/26 | 06/26 | | |
NCT05757219: Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy |
|
|
| Recruiting | 2 | 27 | US | Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy, YESCARTA, Axi-cel | H. Lee Moffitt Cancer Center and Research Institute, Incyte Corporation | Diffuse Large B Cell Lymphoma | 04/25 | 04/26 | | |
NCT04620681: CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML |
|
|
| Active, not recruiting | 1/2 | 19 | US | CD8 Depleted, Non-engrafting,HLA mismatched unrelated donor lymphocytes, Standard of Care Chemotherapy | H. Lee Moffitt Cancer Center and Research Institute | Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia | 07/24 | 07/25 | | |
NCT05127174: Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms |
|
|
| Completed | 1/2 | 12 | US | Fedratinib Pill, Inrebic | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb | Myeloproliferative Neoplasm | 01/25 | 01/25 | | |
NCT03605927: CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease |
|
|
| Completed | 1 | 45 | US | BMS-986004, Anti-CD40L Domain Antibody, Sirolimus, Standard of Care, SIR, Tacrolimus, TAC | H. Lee Moffitt Cancer Center and Research Institute, Bristol-Myers Squibb | Graft-versus-host-disease, GVHD, GVHD, Acute | 09/23 | 09/23 | | |
